urografin-76 and Brain-Diseases

Radiographic contrast agents are associated with a number of adverse effects, including central nervous system effects and seizures. Almost all contrast agents are primarily filtered and excreted by the kidneys, and they accumulate in patients with end-stage renal disease. Brain retention of contrast associated with high doses is a rare event, having been reported only twice in the literature. We report a case of a 49-year-old male on chronic hemodialysis who developed brain retention of contrast resulting in seizures and encephalopathy after receiving large doses of meglumine/sodium diatrizoate during coronary angiography. He was treated successfully with hemodialysis and suffered no permanent neurologic sequelae. Patients with end-stage renal disease may be at increased risk of adverse effects from contrast when administered in high doses.

Topics: Brain Diseases; Contrast Media; Coronary Angiography; Diatrizoate; Diatrizoate Meglumine; Drug Combinations; Follow-Up Studies; Humans; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Seizures; Tomography, X-Ray Computed